Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

The prognostic value of FoxP3 + regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3 + Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL a...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 5; no. 1; p. 15179
Main Authors Shang, Bin, Liu, Yao, Jiang, Shu-juan, Liu, Yi
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 14.10.2015
Nature Publishing Group
Subjects
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/srep15179

Cover

Loading…
Abstract The prognostic value of FoxP3 + regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3 + Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL and Scopus were searched to identify eligible studies. In total, we analyzed 76 articles encompassing 17 types of cancer and including 15,512 cancer cases. The overall pooled analysis including all types of cancer suggested FoxP3 + Tregs had a significant negative effect on overall survival (OS) (OR 1.46, P < 0.001), but the prognostic effect varied greatly according to tumor site. High FoxP3 + Tregs infiltration was significantly associated with shorter OS in the majority of solid tumors studied, including cervical, renal, melanomas and breast cancers, et al ; whereas, FoxP3 + Tregs were associated with improved survival in colorectal, head and neck and oesophageal cancers. The stratified analysis suggested the molecular subtype and tumor stage significantly influenced the prognostic value of FoxP3 + Tregs in certain types of cancer. In conclusion, our meta-analysis suggests that the prognostic role of FoxP3 + Tregs was highly influenced by tumor site and was also correlated with the molecular subtype and tumor stage.
AbstractList The prognostic value of FoxP3 + regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3 + Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched to identify eligible studies. In total, we analyzed 76 articles encompassing 17 types of cancer, and including 15,512 cancer cases. The overall pooled analysis including all types of cancer suggested FoxP3 + Tregs had a significant negative effect on overall survival (OS) (OR 1.46, P < 0.001), but the prognostic effect varied greatly according to tumor site. High FoxP3 + Tregs infiltration was significantly associated with shorter OS in the majority of solid tumors studied, including cervical, renal, melanomas, and breast cancers, et al ; whereas, FoxP3 + Tregs were associated with improved survival in colorectal, head and neck, and oesophageal cancers. The stratified analysis suggested the molecular subtype and tumor stage significantly influenced the prognostic value of FoxP3 + Tregs in certain types of cancer. In conclusion, our meta-analysis suggests that the prognostic role of FoxP3 + Tregs was highly influenced by tumor site, and was also correlated with the molecular subtype and tumor stage.
The prognostic value of FoxP3+ regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3+ Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched to identify eligible studies. In total, we analyzed 76 articles encompassing 17 types of cancer, and including 15,512 cancer cases. The overall pooled analysis including all types of cancer suggested FoxP3+ Tregs had a significant negative effect on overall survival (OS) (OR 1.46, P < 0.001), but the prognostic effect varied greatly according to tumor site. High FoxP3+ Tregs infiltration was significantly associated with shorter OS in the majority of solid tumors studied, including cervical, renal, melanomas, and breast cancers, et al; whereas, FoxP3+ Tregs were associated with improved survival in colorectal, head and neck, and oesophageal cancers. The stratified analysis suggested the molecular subtype and tumor stage significantly influenced the prognostic value of FoxP3+ Tregs in certain types of cancer. In conclusion, our meta-analysis suggests that the prognostic role of FoxP3+ Tregs was highly influenced by tumor site, and was also correlated with the molecular subtype and tumor stage.
ArticleNumber 15179
Author Jiang, Shu-juan
Liu, Yao
Shang, Bin
Liu, Yi
Author_xml – sequence: 1
  givenname: Bin
  surname: Shang
  fullname: Shang, Bin
  organization: Department of thoracic surgery, Provincial Hospital Affiliated to Shandong University
– sequence: 2
  givenname: Yao
  surname: Liu
  fullname: Liu, Yao
  organization: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University
– sequence: 3
  givenname: Shu-juan
  surname: Jiang
  fullname: Jiang, Shu-juan
  organization: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University
– sequence: 4
  givenname: Yi
  surname: Liu
  fullname: Liu, Yi
  organization: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26462617$$D View this record in MEDLINE/PubMed
BookMark eNptkV9vFCEUxYmpsbX2wS9gSHzxT8YCwzDQBxPTWDVpYh_q8-QOCyPNDKzArO63l8nWzVrlBZL7uyfncJ6iIx-8Qeg5Je8oqeV5imZNG9qqR-iEEd5UrGbs6OB9jM5SuiPlNExxqp6gYya4YIK2JyjexDD4kLLTeAPjbHCwOM9TiJXz1o05QnZ-wFfh1039FkczzCPkELf4Fmszjgk7jzV4bWK6wIDTNmUzwSIXzcaZnxj8Ck8mQwUexm1y6Rl6bGFM5uz-PkXfrj7eXn6urr9--nL54brSvJa5Utb0K2uhASGUsBwktYqApkRJ2QJf2V5zU4umlw3tW61qMLJRjWINEb1i9Sl6v9Ndz_1kVtr4Embs1tFNELddANf9PfHuezeETccF4bxdBF7dC8TwYzYpd5NLS2jwJsypoy1jnJFayIK-fIDehTmWwIWSSrVScikK9eLQ0d7KnzoK8HoH6BhSKdbuEUq6pe1u33Zhzx-w2uXy8WEJ48b_brzZbaSi6gcTD0z-A_8G77q8tg
CitedBy_id crossref_primary_10_1007_s40259_018_0277_2
crossref_primary_10_1016_j_devcel_2023_05_010
crossref_primary_10_1016_j_molimm_2024_08_004
crossref_primary_10_1186_s12885_022_10239_6
crossref_primary_10_2478_prolas_2022_0033
crossref_primary_10_3390_cells11132050
crossref_primary_10_1158_1078_0432_CCR_21_2781
crossref_primary_10_1371_journal_pone_0305648
crossref_primary_10_1038_s41379_021_00868_w
crossref_primary_10_1073_pnas_1820388116
crossref_primary_10_1080_2162402X_2017_1284720
crossref_primary_10_3389_fimmu_2021_770390
crossref_primary_10_3390_cells11101672
crossref_primary_10_1186_s40425_018_0418_7
crossref_primary_10_3389_fimmu_2019_01720
crossref_primary_10_3389_fimmu_2020_573920
crossref_primary_10_1016_j_immuni_2023_06_003
crossref_primary_10_17650_1726_9784_2021_20_3_25_33
crossref_primary_10_1007_s00403_024_03758_8
crossref_primary_10_1007_s13402_021_00587_z
crossref_primary_10_1002_2211_5463_12878
crossref_primary_10_1038_s41598_021_98716_z
crossref_primary_10_1126_sciadv_adr7934
crossref_primary_10_3389_fonc_2023_1119343
crossref_primary_10_3390_medicina59020205
crossref_primary_10_3390_ijms19020611
crossref_primary_10_1016_j_ajoms_2019_06_005
crossref_primary_10_1080_2162402X_2016_1186323
crossref_primary_10_1016_j_oooo_2020_02_010
crossref_primary_10_1038_nri_2017_142
crossref_primary_10_3390_cancers11091221
crossref_primary_10_3389_fimmu_2023_1225175
crossref_primary_10_3390_cancers11091223
crossref_primary_10_1136_jitc_2021_002792
crossref_primary_10_1111_his_13987
crossref_primary_10_4049_jimmunol_2200041
crossref_primary_10_18632_oncotarget_9130
crossref_primary_10_4236_ojog_2021_112017
crossref_primary_10_18632_oncotarget_11039
crossref_primary_10_1007_s10528_024_10667_y
crossref_primary_10_1111_imm_12954
crossref_primary_10_1038_s41392_021_00658_5
crossref_primary_10_12677_hjbm_2024_144061
crossref_primary_10_1155_2018_9325261
crossref_primary_10_3390_life11121318
crossref_primary_10_3389_fimmu_2024_1415457
crossref_primary_10_18632_aging_204860
crossref_primary_10_3389_fimmu_2024_1379376
crossref_primary_10_1016_j_cytogfr_2017_04_001
crossref_primary_10_1002_mc_23196
crossref_primary_10_18027_2224_5057_2022_2_3s1_3_8
crossref_primary_10_3389_fimmu_2021_627932
crossref_primary_10_1515_hsz_2020_0326
crossref_primary_10_1016_j_critrevonc_2020_103041
crossref_primary_10_1038_cr_2016_151
crossref_primary_10_3389_fimmu_2019_00650
crossref_primary_10_1038_s41392_023_01471_y
crossref_primary_10_1080_23808993_2019_1634471
crossref_primary_10_3389_fimmu_2019_00653
crossref_primary_10_1016_j_immuni_2017_08_014
crossref_primary_10_1038_s41416_021_01331_y
crossref_primary_10_3389_fimmu_2024_1326753
crossref_primary_10_1007_s00432_022_04101_2
crossref_primary_10_1016_j_cellimm_2017_05_007
crossref_primary_10_1126_scitranslmed_abf8495
crossref_primary_10_3390_cancers13112638
crossref_primary_10_3390_cancers13020210
crossref_primary_10_1158_1078_0432_CCR_17_0162
crossref_primary_10_18632_oncotarget_17722
crossref_primary_10_1002_eji_201847659
crossref_primary_10_3390_ijms24097956
crossref_primary_10_1186_s13046_021_01983_x
crossref_primary_10_1038_bjc_2017_269
crossref_primary_10_1038_s41551_022_00977_0
crossref_primary_10_3389_fonc_2020_00614
crossref_primary_10_1007_s12307_017_0198_5
crossref_primary_10_1038_s41416_021_01660_y
crossref_primary_10_1158_0008_5472_CAN_18_3622
crossref_primary_10_1016_j_canlet_2020_12_021
crossref_primary_10_3389_fonc_2022_815223
crossref_primary_10_3389_fmolb_2021_717038
crossref_primary_10_1177_15330338211045820
crossref_primary_10_3390_cancers11020227
crossref_primary_10_1002_jcp_31327
crossref_primary_10_3390_cancers14071785
crossref_primary_10_3390_healthcare7030108
crossref_primary_10_1016_j_bbcan_2017_05_001
crossref_primary_10_3390_cells9061503
crossref_primary_10_1155_2022_8757656
crossref_primary_10_3389_fimmu_2018_02165
crossref_primary_10_1007_s00262_020_02722_5
crossref_primary_10_1111_cas_14135
crossref_primary_10_3390_biomedicines9060653
crossref_primary_10_3390_medicina55060307
crossref_primary_10_5021_ad_22_175
crossref_primary_10_1007_s00432_020_03398_1
crossref_primary_10_1128_spectrum_04596_22
crossref_primary_10_1097_MD_0000000000030192
crossref_primary_10_4103_tcmj_tcmj_162_20
crossref_primary_10_3389_fimmu_2017_01617
crossref_primary_10_1182_blood_2023022000
crossref_primary_10_1158_0008_5472_CAN_22_0654
crossref_primary_10_1136_jitc_2021_002865
crossref_primary_10_1158_2326_6066_CIR_23_0573
crossref_primary_10_1158_2326_6066_CIR_20_0034
crossref_primary_10_12677_acm_2024_1472004
crossref_primary_10_3389_fimmu_2022_793234
crossref_primary_10_1016_j_molimm_2021_02_014
crossref_primary_10_1038_s10038_018_0468_1
crossref_primary_10_1080_10408363_2019_1660303
crossref_primary_10_1080_2162402X_2016_1150398
crossref_primary_10_3389_fmed_2022_1026521
crossref_primary_10_1111_pin_13099
crossref_primary_10_1016_j_ejca_2023_05_019
crossref_primary_10_1111_cas_15136
crossref_primary_10_1016_j_ejca_2024_113535
crossref_primary_10_3390_cells9112364
crossref_primary_10_1002_JLB_5MR0717_275RR
crossref_primary_10_1146_annurev_immunol_042718_041717
crossref_primary_10_1038_s41598_021_02449_y
crossref_primary_10_1097_01_XEJ_0000534717_60403_bb
crossref_primary_10_3389_fimmu_2023_1275890
crossref_primary_10_1016_j_intimp_2023_110038
crossref_primary_10_1111_jop_12927
crossref_primary_10_1002_cam4_4017
crossref_primary_10_1186_s12885_018_5117_8
crossref_primary_10_1016_j_cell_2019_02_005
crossref_primary_10_1016_j_genrep_2022_101694
crossref_primary_10_1136_jitc_2021_002873
crossref_primary_10_20517_cdr_2023_46
crossref_primary_10_20517_cdr_2023_47
crossref_primary_10_20538_1682_0363_2022_1_171_182
crossref_primary_10_1080_2162402X_2023_2247303
crossref_primary_10_3390_cancers16132296
crossref_primary_10_1007_s00262_020_02517_8
crossref_primary_10_1016_j_canlet_2018_07_024
crossref_primary_10_1038_nrd_2018_148
crossref_primary_10_1038_s41590_021_00930_4
crossref_primary_10_1093_immadv_ltaa001
crossref_primary_10_1158_1055_9965_EPI_20_0714
crossref_primary_10_1172_jci_insight_95692
crossref_primary_10_1097_MD_0000000000031382
crossref_primary_10_1038_s41467_021_21573_x
crossref_primary_10_1007_s00262_020_02604_w
crossref_primary_10_1002_jso_25091
crossref_primary_10_1038_s41698_024_00748_x
crossref_primary_10_1186_s13000_019_0900_7
crossref_primary_10_1007_s00103_020_03230_8
crossref_primary_10_1136_jitc_2020_001355
crossref_primary_10_3389_fimmu_2020_01633
crossref_primary_10_1136_gutjnl_2018_316510
crossref_primary_10_3389_fimmu_2021_832942
crossref_primary_10_3389_fimmu_2024_1433299
crossref_primary_10_1038_s41368_022_00160_w
crossref_primary_10_7554_eLife_69015
crossref_primary_10_1038_s41598_018_21861_5
crossref_primary_10_1152_physrev_00018_2019
crossref_primary_10_3389_fimmu_2021_783282
crossref_primary_10_1158_2326_6066_CIR_22_0699
crossref_primary_10_1111_sji_13322
crossref_primary_10_1016_j_ccell_2023_02_014
crossref_primary_10_1080_2162402X_2024_2320411
crossref_primary_10_1111_cei_13567
crossref_primary_10_3390_cancers11020140
crossref_primary_10_1186_s12917_019_2100_9
crossref_primary_10_1227_neu_0000000000002237
crossref_primary_10_2139_ssrn_3155506
crossref_primary_10_1016_j_jbior_2020_100722
crossref_primary_10_3389_fimmu_2024_1403771
crossref_primary_10_3390_ijms22020867
crossref_primary_10_1016_j_isci_2022_105529
crossref_primary_10_1016_j_canlet_2019_10_032
crossref_primary_10_1186_s40425_019_0690_1
crossref_primary_10_1016_j_euros_2020_06_003
crossref_primary_10_3389_fonc_2021_649710
crossref_primary_10_1371_journal_pone_0315284
crossref_primary_10_3390_cancers15041262
crossref_primary_10_1016_j_molimm_2019_11_008
crossref_primary_10_1136_jitc_2021_002383
crossref_primary_10_3390_biomedicines13010134
crossref_primary_10_1007_s11523_017_0547_9
crossref_primary_10_1080_07357907_2017_1309545
crossref_primary_10_3390_cancers14010205
crossref_primary_10_1093_narcan_zcad055
crossref_primary_10_3892_ol_2019_10896
crossref_primary_10_1002_eji_202250258
crossref_primary_10_1016_j_iotech_2019_05_001
crossref_primary_10_3389_fimmu_2022_903564
crossref_primary_10_3390_cancers11081128
crossref_primary_10_3390_vaccines10050740
crossref_primary_10_1155_2022_5851755
crossref_primary_10_3389_fimmu_2022_855849
crossref_primary_10_1016_j_immuni_2017_03_013
crossref_primary_10_1016_j_heliyon_2018_e00880
crossref_primary_10_1186_s12935_020_01517_z
crossref_primary_10_1007_s00262_019_02327_7
crossref_primary_10_1016_j_ccell_2023_04_003
crossref_primary_10_3389_fonc_2020_01211
crossref_primary_10_1016_j_heliyon_2024_e26094
crossref_primary_10_1016_j_ymthe_2017_05_006
crossref_primary_10_1158_1055_9965_EPI_21_1334
crossref_primary_10_1158_0008_5472_CAN_20_1885
crossref_primary_10_3390_cells13121057
crossref_primary_10_1007_s00011_019_01215_1
crossref_primary_10_1186_s13018_024_04885_8
crossref_primary_10_1080_21645515_2022_2060019
crossref_primary_10_1016_j_jid_2019_03_1162
crossref_primary_10_1002_2056_4538_12386
crossref_primary_10_1080_1744666X_2023_2262140
crossref_primary_10_3389_fonc_2024_1442103
crossref_primary_10_1007_s00262_019_02349_1
crossref_primary_10_1155_2022_1094607
crossref_primary_10_3389_fimmu_2021_792691
crossref_primary_10_1016_j_jconrel_2022_06_024
crossref_primary_10_3389_fonc_2023_1182434
crossref_primary_10_1080_2162402X_2019_1593806
crossref_primary_10_1111_cup_14381
crossref_primary_10_3389_fmolb_2021_583028
crossref_primary_10_3390_cells11182826
crossref_primary_10_61186_ijbc_16_4_56
crossref_primary_10_1002_hed_26158
crossref_primary_10_3389_fimmu_2021_717421
crossref_primary_10_3390_cancers13225748
crossref_primary_10_1158_2326_6066_CIR_17_0466
crossref_primary_10_2147_IJGM_S439190
crossref_primary_10_1186_s40425_019_0708_8
crossref_primary_10_3390_cancers15061901
crossref_primary_10_1186_s12935_022_02626_7
crossref_primary_10_3390_cancers11091398
crossref_primary_10_3390_cancers12020284
crossref_primary_10_3390_vaccines12060633
crossref_primary_10_3390_cancers12020287
crossref_primary_10_3390_ijms22010190
crossref_primary_10_1016_j_arr_2025_102715
crossref_primary_10_1634_theoncologist_2019_0123
crossref_primary_10_3390_ijms23158707
crossref_primary_10_3390_biomedicines6010025
crossref_primary_10_3390_ijms241411673
crossref_primary_10_1016_j_intimp_2019_105965
crossref_primary_10_1159_000531024
crossref_primary_10_3390_vaccines8020259
crossref_primary_10_1007_s12672_023_00787_z
crossref_primary_10_1158_1078_0432_CCR_20_0328
crossref_primary_10_1172_jci_insight_151035
crossref_primary_10_1021_acsptsci_4c00358
crossref_primary_10_1038_s41598_017_08128_1
crossref_primary_10_1186_s12967_022_03667_2
crossref_primary_10_1038_s41540_024_00387_9
crossref_primary_10_1007_s00432_023_05499_z
crossref_primary_10_3389_fimmu_2022_1038927
crossref_primary_10_1038_s41467_019_09416_2
crossref_primary_10_1038_ncomms15365
crossref_primary_10_1242_dmm_036236
crossref_primary_10_1080_15384101_2022_2029996
crossref_primary_10_18632_oncotarget_17340
crossref_primary_10_1016_j_cps_2021_06_005
crossref_primary_10_1155_2022_4954457
crossref_primary_10_1016_j_semcancer_2021_03_036
crossref_primary_10_1016_j_compbiomed_2025_110021
crossref_primary_10_1080_10715762_2023_2193308
crossref_primary_10_1158_0008_5472_CAN_18_0365
crossref_primary_10_1016_j_ccell_2024_05_013
crossref_primary_10_1186_s12935_021_01766_6
crossref_primary_10_3390_cancers14092214
crossref_primary_10_1111_exd_14721
crossref_primary_10_3390_cancers14163862
crossref_primary_10_1371_journal_pone_0191065
crossref_primary_10_2139_ssrn_4170185
crossref_primary_10_3390_jcm11051432
crossref_primary_10_1007_s40944_023_00756_y
crossref_primary_10_4049_jimmunol_1701703
crossref_primary_10_3389_fddev_2022_823412
crossref_primary_10_3390_cells12192404
crossref_primary_10_3390_ijms21093352
crossref_primary_10_1016_S1877_1203_22_00122_7
crossref_primary_10_1080_2162402X_2018_1442999
crossref_primary_10_1038_s41418_021_00892_y
crossref_primary_10_1016_j_biomaterials_2019_04_024
crossref_primary_10_3389_fimmu_2022_866937
crossref_primary_10_1186_s12885_024_12603_0
crossref_primary_10_1155_2019_5981054
crossref_primary_10_3390_cancers15113046
crossref_primary_10_1177_1010428320971404
crossref_primary_10_1016_j_ygyno_2022_10_022
crossref_primary_10_3389_fcimb_2021_649815
crossref_primary_10_1016_j_bioorg_2022_106141
crossref_primary_10_14639_0392_100X_2481
crossref_primary_10_3390_vaccines8010111
crossref_primary_10_1172_jci_insight_154646
crossref_primary_10_3389_fimmu_2020_616949
crossref_primary_10_3389_fimmu_2023_1328651
crossref_primary_10_3390_cancers15092420
crossref_primary_10_1002_hed_27040
crossref_primary_10_1007_s00251_022_01291_4
crossref_primary_10_1007_s12253_019_00695_0
crossref_primary_10_3389_fimmu_2024_1355945
crossref_primary_10_1016_j_bcp_2021_114697
crossref_primary_10_3389_fonc_2019_00827
crossref_primary_10_1007_s00262_019_02317_9
crossref_primary_10_1007_s00262_018_2248_3
crossref_primary_10_1186_s12935_021_02024_5
crossref_primary_10_1136_jitc_2021_003892
crossref_primary_10_3389_fphar_2019_00200
crossref_primary_10_1158_1078_0432_CCR_19_1872
crossref_primary_10_18027_2224_5057_2024_029
crossref_primary_10_1093_oncolo_oyad199
crossref_primary_10_1016_j_coi_2024_102511
crossref_primary_10_3390_cancers12092692
crossref_primary_10_2482_haigan_64_310
crossref_primary_10_1007_s00262_020_02645_1
crossref_primary_10_3389_fonc_2021_684098
crossref_primary_10_1016_j_oraloncology_2019_104560
crossref_primary_10_1186_s12935_021_02378_w
crossref_primary_10_3389_fimmu_2018_00232
crossref_primary_10_3892_ol_2018_9226
crossref_primary_10_1016_j_clon_2018_05_008
crossref_primary_10_1002_jcb_29613
crossref_primary_10_18632_oncotarget_11943
crossref_primary_10_3389_fimmu_2021_718621
crossref_primary_10_1007_s00441_016_2474_y
crossref_primary_10_1080_1744666X_2024_2334258
crossref_primary_10_1002_ijc_32571
crossref_primary_10_1016_j_ejca_2016_03_085
crossref_primary_10_1080_01616412_2016_1188473
crossref_primary_10_3389_fimmu_2017_00341
crossref_primary_10_1002_adhm_202001415
crossref_primary_10_1007_s00262_020_02842_y
crossref_primary_10_1016_j_labinv_2025_104094
crossref_primary_10_3390_cancers13235878
crossref_primary_10_1007_s00262_020_02657_x
crossref_primary_10_3390_healthcare10020342
crossref_primary_10_1016_j_modpat_2023_100218
crossref_primary_10_1038_nrc_2017_86
crossref_primary_10_24060_2076_3093_2021_11_4_328_336
crossref_primary_10_1016_j_vetimm_2018_06_011
crossref_primary_10_3389_fphys_2017_00950
crossref_primary_10_1007_s00262_020_02633_5
crossref_primary_10_1016_j_meegid_2018_08_014
crossref_primary_10_3390_cancers13010048
crossref_primary_10_1146_annurev_med_060116_022926
crossref_primary_10_1136_jitc_2021_002339
crossref_primary_10_1080_15384047_2016_1235666
crossref_primary_10_1038_s12276_018_0130_1
crossref_primary_10_1073_pnas_1810580115
crossref_primary_10_1080_2162402X_2020_1841948
crossref_primary_10_1186_s12967_020_02336_6
crossref_primary_10_1007_s12029_020_00376_1
crossref_primary_10_3389_fmolb_2022_833771
crossref_primary_10_1007_s00432_021_03753_w
crossref_primary_10_1016_j_oraloncology_2017_02_023
crossref_primary_10_3390_molecules23061308
crossref_primary_10_1186_s13040_024_00404_x
crossref_primary_10_1038_s41576_024_00761_7
crossref_primary_10_1080_21645515_2021_1891817
crossref_primary_10_1002_eji_201948470
crossref_primary_10_1016_j_heliyon_2024_e34632
crossref_primary_10_3389_fimmu_2023_1337333
crossref_primary_10_1111_imm_13494
crossref_primary_10_1097_MD_0000000000026017
crossref_primary_10_1101_cshperspect_a037044
crossref_primary_10_3390_ijms22010450
crossref_primary_10_1016_j_jhep_2020_11_036
crossref_primary_10_1126_sciimmunol_adf6717
crossref_primary_10_1158_2767_9764_CRC_24_0257
crossref_primary_10_1038_s41416_020_0943_2
crossref_primary_10_1186_s12943_018_0913_y
crossref_primary_10_1002_cac2_12546
crossref_primary_10_1007_s11255_020_02592_x
crossref_primary_10_1016_j_jid_2018_06_178
crossref_primary_10_1038_s41598_024_80489_w
crossref_primary_10_1155_2018_1812535
crossref_primary_10_3389_fonc_2023_1134063
crossref_primary_10_1007_s00262_021_03033_z
crossref_primary_10_3390_cancers13071587
crossref_primary_10_1007_s10238_024_01362_8
crossref_primary_10_3390_cancers10020039
crossref_primary_10_1111_imm_13016
crossref_primary_10_1155_2018_9128754
crossref_primary_10_1080_2162402X_2017_1341030
crossref_primary_10_3389_fped_2020_00454
crossref_primary_10_1016_j_pathol_2016_10_005
crossref_primary_10_3390_cancers14225560
crossref_primary_10_1155_2022_4946197
crossref_primary_10_3390_ijms24021527
crossref_primary_10_1016_j_jare_2024_07_030
crossref_primary_10_1152_ajpcell_00189_2022
crossref_primary_10_1016_j_addr_2019_06_005
crossref_primary_10_3390_cancers12102870
crossref_primary_10_1007_s13273_019_0017_9
crossref_primary_10_3390_cancers12071826
crossref_primary_10_1080_2162402X_2020_1760067
crossref_primary_10_1021_acsnano_8b05893
crossref_primary_10_3389_fonc_2021_662010
crossref_primary_10_1016_j_lungcan_2018_10_021
crossref_primary_10_3389_fimmu_2021_662134
crossref_primary_10_1002_lary_29689
crossref_primary_10_3390_ijms25126377
crossref_primary_10_12677_acm_2025_151069
crossref_primary_10_1158_1535_7163_MCT_20_0464
crossref_primary_10_1016_j_ccell_2021_09_008
crossref_primary_10_1371_journal_pone_0252480
crossref_primary_10_1007_s00262_020_02686_6
crossref_primary_10_1146_annurev_immunol_070621_030155
crossref_primary_10_1007_s00262_020_02784_5
crossref_primary_10_1016_j_bcmd_2016_04_004
crossref_primary_10_1158_2326_6066_CIR_20_0637
crossref_primary_10_1080_03009734_2018_1555195
crossref_primary_10_1016_j_semcancer_2022_01_006
crossref_primary_10_4049_jimmunol_2001203
crossref_primary_10_5858_arpa_2021_0169_OA
crossref_primary_10_1073_pnas_1815087116
crossref_primary_10_3390_ijms21249705
crossref_primary_10_1007_s11912_020_00938_3
crossref_primary_10_3390_cancers15092453
crossref_primary_10_3390_jcm9051383
crossref_primary_10_1038_s41598_018_28277_1
crossref_primary_10_1080_14712598_2021_1825679
crossref_primary_10_1016_j_nantod_2020_101045
crossref_primary_10_1002_wsbm_1539
crossref_primary_10_1016_j_trecan_2019_11_003
crossref_primary_10_1177_0300985818808530
crossref_primary_10_1016_j_mam_2020_100936
crossref_primary_10_1016_j_heliyon_2022_e10450
crossref_primary_10_1042_BCJ20210233
crossref_primary_10_1007_s13402_021_00601_4
crossref_primary_10_1038_s41598_022_27237_0
crossref_primary_10_1038_s43018_020_00155_8
crossref_primary_10_1158_1078_0432_CCR_18_1100
crossref_primary_10_1097_XCS_0000000000000440
crossref_primary_10_1186_s12935_022_02684_x
crossref_primary_10_3389_fgene_2022_948734
crossref_primary_10_3389_fimmu_2021_723609
crossref_primary_10_1126_sciimmunol_abn6173
crossref_primary_10_1158_1078_0432_CCR_22_1843
crossref_primary_10_1038_s41467_017_02289_3
crossref_primary_10_1002_lary_28336
crossref_primary_10_1038_s41598_024_60049_y
crossref_primary_10_1172_jci_insight_93652
crossref_primary_10_1016_j_canlet_2023_216441
crossref_primary_10_1016_j_semcancer_2019_01_006
crossref_primary_10_1136_jitc_2024_009662
crossref_primary_10_1016_j_molimm_2016_12_018
crossref_primary_10_3390_ijms22158030
crossref_primary_10_1186_s12885_023_10590_2
crossref_primary_10_3390_cancers14194887
crossref_primary_10_1016_j_heliyon_2025_e41736
crossref_primary_10_3390_vaccines4030028
crossref_primary_10_1186_s12967_023_03949_3
crossref_primary_10_18632_oncotarget_24835
crossref_primary_10_3389_fimmu_2022_968165
crossref_primary_10_3390_cancers14122876
crossref_primary_10_1186_s12943_019_0938_x
crossref_primary_10_3390_cancers14122991
crossref_primary_10_3389_fimmu_2019_02453
crossref_primary_10_1002_hed_27671
crossref_primary_10_1016_j_imbio_2024_152822
crossref_primary_10_1186_s12967_020_02624_1
crossref_primary_10_3748_wjg_v24_i17_1839
crossref_primary_10_3389_fimmu_2018_00610
crossref_primary_10_1007_s00432_016_2223_3
crossref_primary_10_3389_fonc_2022_1021609
crossref_primary_10_3390_cancers15061642
crossref_primary_10_1080_21691401_2018_1482306
crossref_primary_10_3390_cells13050413
crossref_primary_10_1016_j_molimm_2016_12_001
crossref_primary_10_3390_ijms25137346
crossref_primary_10_1186_s41065_025_00381_z
crossref_primary_10_1016_j_celrep_2018_10_047
crossref_primary_10_1136_jitc_2021_004378
crossref_primary_10_3389_fonc_2021_660039
crossref_primary_10_1111_1759_7714_15493
crossref_primary_10_1038_s41590_019_0429_7
crossref_primary_10_1016_j_trecan_2017_06_005
crossref_primary_10_1016_j_celrep_2017_06_062
crossref_primary_10_1016_j_ejca_2018_06_023
crossref_primary_10_1080_2162402X_2023_2192100
crossref_primary_10_1038_s41525_018_0054_7
crossref_primary_10_3390_cancers16234011
crossref_primary_10_1155_2020_2134647
crossref_primary_10_1111_imm_13562
crossref_primary_10_1016_j_omtn_2021_05_005
crossref_primary_10_3389_fonc_2024_1325575
crossref_primary_10_1186_s12967_022_03736_6
crossref_primary_10_3390_cancers13061440
crossref_primary_10_3390_cells10123309
crossref_primary_10_1038_s41598_019_40487_9
crossref_primary_10_3390_cells11223600
crossref_primary_10_1007_s00795_023_00367_8
crossref_primary_10_1186_s12967_023_04686_3
crossref_primary_10_3390_cancers14225539
crossref_primary_10_1002_anbr_202100006
crossref_primary_10_1007_s00262_023_03517_0
crossref_primary_10_3389_fimmu_2022_981479
crossref_primary_10_1007_s00292_018_0541_8
crossref_primary_10_1016_j_molimm_2023_04_005
crossref_primary_10_3389_fimmu_2023_1267279
crossref_primary_10_1097_MD_0000000000039998
crossref_primary_10_1152_physiol_00020_2022
crossref_primary_10_1007_s10528_022_10317_1
crossref_primary_10_1002_jev2_12390
crossref_primary_10_3390_v14050986
crossref_primary_10_1016_j_clgc_2024_01_008
crossref_primary_10_1186_s12885_019_5745_7
crossref_primary_10_1097_ot9_0000000000000041
crossref_primary_10_1172_jci_insight_161438
crossref_primary_10_1016_j_immuni_2023_09_004
crossref_primary_10_3390_biology10080808
crossref_primary_10_1016_j_celrep_2019_10_120
crossref_primary_10_2147_CMAR_S285128
crossref_primary_10_18632_oncotarget_21331
crossref_primary_10_3390_ijms24119279
crossref_primary_10_1002_cti2_1165
crossref_primary_10_3802_jgo_2023_34_e16
crossref_primary_10_1186_s12957_019_1621_9
crossref_primary_10_1016_j_omto_2023_01_001
crossref_primary_10_1111_imr_13287
crossref_primary_10_3389_fonc_2020_570819
crossref_primary_10_1002_eji_201847597
crossref_primary_10_1042_CS20210042
crossref_primary_10_1186_s12979_020_0174_7
crossref_primary_10_4049_jimmunol_1701188
crossref_primary_10_3390_cells10010045
crossref_primary_10_1172_JCI159283
crossref_primary_10_1097_SLA_0000000000002754
crossref_primary_10_1007_s00262_016_1902_x
crossref_primary_10_1016_j_labinv_2024_102126
crossref_primary_10_3389_fimmu_2019_00911
crossref_primary_10_1016_j_tranon_2018_03_007
crossref_primary_10_1158_0008_5472_CAN_23_0613
crossref_primary_10_1007_s00262_021_02881_z
crossref_primary_10_3389_fimmu_2022_994019
crossref_primary_10_3390_biomedicines11010189
crossref_primary_10_1038_s41598_025_85444_x
crossref_primary_10_2147_JIR_S303750
crossref_primary_10_1080_15440478_2021_1993407
crossref_primary_10_1007_s00432_018_2602_z
crossref_primary_10_1038_s41598_020_60255_4
crossref_primary_10_1016_j_xinn_2021_100194
crossref_primary_10_1080_2162402X_2017_1356148
crossref_primary_10_1016_j_immuni_2016_10_032
crossref_primary_10_18632_oncotarget_24504
crossref_primary_10_1016_j_canlet_2017_10_014
crossref_primary_10_1016_j_tranon_2022_101469
crossref_primary_10_3389_fgene_2023_1265866
crossref_primary_10_3390_cancers10090302
crossref_primary_10_1073_pnas_1812186116
crossref_primary_10_1080_2162402X_2018_1426519
crossref_primary_10_1038_s41379_022_01086_8
crossref_primary_10_1111_cei_13060
crossref_primary_10_18632_aging_202842
crossref_primary_10_1007_s00262_018_2288_8
crossref_primary_10_1136_jclinpath_2016_203978
crossref_primary_10_3389_fonc_2021_663749
crossref_primary_10_1016_j_adro_2018_08_018
crossref_primary_10_1007_s11427_018_9428_9
crossref_primary_10_2147_JIR_S441981
crossref_primary_10_1002_cam4_7059
crossref_primary_10_1002_eji_202350448
crossref_primary_10_1007_s00106_019_00758_3
crossref_primary_10_1002_eji_202451225
crossref_primary_10_3389_fimmu_2022_1001161
crossref_primary_10_1080_2162402X_2023_2175517
crossref_primary_10_1177_10732748211004878
crossref_primary_10_1186_s13014_021_01868_5
crossref_primary_10_2147_BCTT_S470570
crossref_primary_10_2147_JIR_S249384
crossref_primary_10_1016_j_cpt_2022_11_001
crossref_primary_10_1155_2021_8865791
crossref_primary_10_3389_fimmu_2022_1069192
crossref_primary_10_3390_cancers14092071
crossref_primary_10_3390_vaccines13020117
crossref_primary_10_3389_fmed_2022_834725
crossref_primary_10_1016_j_intimp_2023_110015
crossref_primary_10_1038_s41420_023_01765_8
crossref_primary_10_1186_s13046_023_02805_y
crossref_primary_10_1093_annonc_mdx238
crossref_primary_10_3389_fimmu_2023_1259562
crossref_primary_10_1002_cam4_2611
crossref_primary_10_1016_j_euf_2021_04_014
crossref_primary_10_1016_j_cllc_2023_06_013
crossref_primary_10_3389_fphys_2020_511071
crossref_primary_10_3389_fonc_2023_1201497
crossref_primary_10_37349_emed_2023_00197
crossref_primary_10_1080_2162402X_2017_1338236
crossref_primary_10_1111_imm_12779
crossref_primary_10_3390_cancers14061580
crossref_primary_10_1007_s11684_018_0663_7
crossref_primary_10_3389_fonc_2022_1008714
crossref_primary_10_1016_j_jncc_2022_10_002
crossref_primary_10_3389_fcell_2021_725473
crossref_primary_10_1007_s00432_023_04916_7
crossref_primary_10_3389_fonc_2024_1346793
crossref_primary_10_1158_1940_6207_CAPR_22_0193
crossref_primary_10_1002_ijc_34281
crossref_primary_10_1007_s40259_020_00449_4
crossref_primary_10_1038_s41422_020_0337_2
crossref_primary_10_1080_02648725_2023_2166706
crossref_primary_10_3389_fonc_2021_625207
crossref_primary_10_3389_fcell_2021_726205
crossref_primary_10_3390_ijms20235822
crossref_primary_10_4049_jimmunol_1701021
crossref_primary_10_3390_ijms22084049
crossref_primary_10_1007_s00428_019_02565_1
crossref_primary_10_2147_OTT_S264312
crossref_primary_10_3389_fimmu_2022_892543
crossref_primary_10_1002_btm2_10314
crossref_primary_10_1016_j_jid_2020_10_011
crossref_primary_10_1177_0300985820960131
crossref_primary_10_1016_j_oraloncology_2020_105084
crossref_primary_10_3390_cancers13051018
crossref_primary_10_1002_jmv_25312
crossref_primary_10_1155_2017_5458178
crossref_primary_10_1186_s13058_019_1176_2
crossref_primary_10_3389_fimmu_2024_1501885
crossref_primary_10_3390_cancers15215232
crossref_primary_10_1007_s00262_017_2040_9
crossref_primary_10_1080_2162402X_2017_1288331
crossref_primary_10_3390_ijms23052496
crossref_primary_10_3389_fimmu_2017_01900
crossref_primary_10_2174_1381612826666200713171137
crossref_primary_10_1038_s41416_022_01875_7
crossref_primary_10_3389_fimmu_2019_01078
crossref_primary_10_1002_cam4_7368
crossref_primary_10_1016_j_humpath_2017_12_022
crossref_primary_10_1126_sciimmunol_abn0175
crossref_primary_10_1186_s40364_020_00257_6
crossref_primary_10_2147_CMAR_S265828
crossref_primary_10_1001_jamaoncol_2017_3684
crossref_primary_10_1186_s13045_018_0629_x
crossref_primary_10_1007_s00795_021_00290_w
crossref_primary_10_3857_roj_2021_00472
crossref_primary_10_1080_2162402X_2018_1537693
crossref_primary_10_1016_j_pathol_2021_10_002
crossref_primary_10_1158_2767_9764_CRC_24_0638
crossref_primary_10_1007_s12254_016_0270_8
crossref_primary_10_3389_fimmu_2022_835690
crossref_primary_10_1016_j_canlet_2020_07_022
crossref_primary_10_3390_cells13110941
crossref_primary_10_1155_2022_9593039
crossref_primary_10_3390_ijms25074134
crossref_primary_10_3390_ijms25126501
crossref_primary_10_1016_j_arabjc_2021_103121
crossref_primary_10_1007_s13402_024_00992_0
crossref_primary_10_18632_aging_102499
crossref_primary_10_1007_s00262_020_02694_6
crossref_primary_10_1016_j_bbmt_2017_11_012
crossref_primary_10_1136_jitc_2020_001749
crossref_primary_10_1016_j_prp_2021_153703
crossref_primary_10_1186_s12885_024_12851_0
crossref_primary_10_1016_j_canlet_2024_217086
crossref_primary_10_1002_cam4_5194
crossref_primary_10_1080_2162402X_2019_1614858
crossref_primary_10_3390_diagnostics12122987
crossref_primary_10_1002_jcp_29842
crossref_primary_10_2174_1386207325666220324092231
crossref_primary_10_1016_j_neo_2024_101091
crossref_primary_10_18632_oncotarget_26748
crossref_primary_10_1016_j_ctrv_2022_102499
crossref_primary_10_2147_CMAR_S460315
crossref_primary_10_1007_s13770_023_00585_2
crossref_primary_10_17650_2222_1468_2022_12_3_114_126
crossref_primary_10_1182_bloodadvances_2023010158
crossref_primary_10_1080_2162402X_2019_1644108
crossref_primary_10_1136_gutjnl_2016_311421
crossref_primary_10_3389_fonc_2021_739182
crossref_primary_10_3390_biomedicines10112732
crossref_primary_10_1371_journal_pone_0307038
crossref_primary_10_3390_biom12010132
crossref_primary_10_1038_s41467_021_26091_4
crossref_primary_10_1186_s12935_020_1104_7
crossref_primary_10_1016_j_crimmu_2023_100074
crossref_primary_10_1136_bmjopen_2021_060659
crossref_primary_10_3390_pharmaceutics14091768
crossref_primary_10_1007_s10120_019_00974_4
crossref_primary_10_1093_discim_kyae006
crossref_primary_10_1080_21645515_2018_1434384
crossref_primary_10_1007_s00432_023_05187_y
crossref_primary_10_1038_s41598_022_23016_z
crossref_primary_10_1111_cei_13044
crossref_primary_10_1016_j_xcrm_2021_100399
Cites_doi 10.1002/sim.1186
10.1016/j.ejca.2008.05.017
10.1002/cncr.24317
10.1038/nm1093
10.1186/1745-6215-8-16
10.1182/blood-2006-04-018218
10.1158/0008-5472.CAN-04-3104
10.1038/cmi.2010.56
10.1007/s12253-010-9254-x
10.1038/sj.bjc.6602201
10.1007/s00432-010-0816-9
10.1200/JCO.2008.18.7229
10.1002/eji.200324181
10.1007/s10585-013-9602-9
10.1097/COC.0b013e318187dd40
10.1007/0-387-26283-0_3
10.1186/bcr2869
10.1002/cncr.22282
10.1158/1078-0432.CCR-11-3216
10.1371/journal.pmed.1000097
10.1126/science.1079490
10.1158/1078-0432.CCR-06-2139
10.1038/bjc.2012.524
10.1126/science.1129139
10.1158/1078-0432.CCR-04-1869
10.1200/JCO.2006.05.9584
10.1007/s00262-012-1277-6
10.4049/jimmunol.177.9.6540
10.1016/j.cell.2008.05.009
10.1002/cncr.25293
10.1073/pnas.0509182102
10.1158/0008-5472.CAN-07-6842
10.1158/0008-5472.CAN-10-1736
10.1111/j.1464-410X.2008.08151.x
10.1007/s00262-008-0583-5
10.1371/journal.pone.0042274
10.1111/bjd.12641
10.1158/1078-0432.CCR-07-4554
10.1200/JCO.2006.09.4565
10.1002/cncr.23712
10.1371/journal.pone.0006412
10.1158/1078-0432.CCR-05-1886
10.1053/j.gastro.2009.06.053
10.1002/ijc.24989
10.1002/cncr.24999
ContentType Journal Article
Copyright The Author(s) 2015
Copyright Nature Publishing Group Oct 2015
Copyright © 2015, Macmillan Publishers Limited 2015 Macmillan Publishers Limited
Copyright_xml – notice: The Author(s) 2015
– notice: Copyright Nature Publishing Group Oct 2015
– notice: Copyright © 2015, Macmillan Publishers Limited 2015 Macmillan Publishers Limited
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1038/srep15179
DatabaseName Springer Nature OA Free Journals (WRLC)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database (ProQuest)
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database

CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 15179
ExternalDocumentID PMC4604472
26462617
10_1038_srep15179
Genre Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
EJD
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7XB
8FK
AARCD
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c438t-9febdffa5a6696f4a81f90ac109887a4dfbc4e365b851b7c93ae859592506b923
IEDL.DBID M48
ISSN 2045-2322
IngestDate Thu Aug 21 14:12:11 EDT 2025
Fri Jul 11 15:38:42 EDT 2025
Wed Aug 13 06:31:34 EDT 2025
Mon Jul 21 06:08:24 EDT 2025
Tue Jul 01 03:15:09 EDT 2025
Thu Apr 24 23:00:46 EDT 2025
Fri Feb 21 02:39:35 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c438t-9febdffa5a6696f4a81f90ac109887a4dfbc4e365b851b7c93ae859592506b923
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-1
ObjectType-Article-3
ObjectType-Undefined-4
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/srep15179
PMID 26462617
PQID 1899788486
PQPubID 2041939
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4604472
proquest_miscellaneous_1722420368
proquest_journals_1899788486
pubmed_primary_26462617
crossref_primary_10_1038_srep15179
crossref_citationtrail_10_1038_srep15179
springer_journals_10_1038_srep15179
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-10-14
PublicationDateYYYYMMDD 2015-10-14
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-10-14
  day: 14
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2015
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Sato (CR3) 2005; 102
Curiel (CR13) 2004; 10
Chiba (CR7) 2004; 91
Galon (CR1) 2006; 313
West (CR31) 2013; 108
Klages (CR44) 2010; 70
Venet (CR39) 2006; 177
Salama (CR19) 2009; 27
Alvaro (CR34) 2005; 11
Ghiringhelli (CR42) 2004; 34
Demir (CR30) 2013; 30
Peng (CR9) 2012; 61
Gerber (CR25) 2014; 170
Shen (CR4) 2010; 136
Yoon (CR8) 2012; 7
Gao (CR14) 2007; 25
Badoual (CR36) 2008; 68
Higgins, Thompson (CR22) 2002; 21
Shah (CR17) 2011; 8
Milne (CR41) 2009; 4
Gerena-Lewis (CR43) 2009; 32
Moher, Liberati, Tetzlaff, Altman (CR20) 2009; 6
Li (CR24) 2009; 103
Miracco (CR28) 2007; 18
Jordanova (CR45) 2008; 14
Badoual (CR18) 2006; 12
Leffers (CR2) 2009; 58
Bates (CR12) 2006; 24
Carreras (CR35) 2006; 108
Yan (CR29) 2011; 13
deLeeuw, Kost, Kakal, Nelson (CR5) 2012; 18
Hori, Nomura, Sakaguchi (CR10) 2003; 299
Petersen (CR15) 2006; 107
Kawai (CR6) 2008; 113
Mougiakakos (CR26) 2010; 116
Sinicrope (CR46) 2009; 137
Frey (CR32) 2010; 126
Perrone (CR16) 2008; 44
Tierney, Stewart, Ghersi, Burdett, Sydes (CR21) 2007; 8
Erdman (CR38) 2005; 65
Lee, Park, Lee, Yun, Chun (CR33) 2010; 116
Ladanyi (CR27) 2010; 16
Sakaguchi, Yamaguchi, Nomura, Ono (CR11) 2008; 133
Schottelius, Dinter (CR37) 2006; 130
Adams (CR40) 2009; 115
Siddiqui (CR23) 2007; 13
T Chiba (BFsrep15179_CR7) 2004; 91
D Mougiakakos (BFsrep15179_CR26) 2010; 116
T Alvaro (BFsrep15179_CR34) 2005; 11
K1 Klages (BFsrep15179_CR44) 2010; 70
DM Frey (BFsrep15179_CR32) 2010; 126
S Hori (BFsrep15179_CR10) 2003; 299
F Ghiringhelli (BFsrep15179_CR42) 2004; 34
JP Higgins (BFsrep15179_CR22) 2002; 21
JF Tierney (BFsrep15179_CR21) 2007; 8
L Demir (BFsrep15179_CR30) 2013; 30
J Galon (BFsrep15179_CR1) 2006; 313
W Shah (BFsrep15179_CR17) 2011; 8
NR West (BFsrep15179_CR31) 2013; 108
C Badoual (BFsrep15179_CR36) 2008; 68
E Sato (BFsrep15179_CR3) 2005; 102
JF Li (BFsrep15179_CR24) 2009; 103
K Milne (BFsrep15179_CR41) 2009; 4
O Kawai (BFsrep15179_CR6) 2008; 113
C Badoual (BFsrep15179_CR18) 2006; 12
HH Yoon (BFsrep15179_CR8) 2012; 7
D Moher (BFsrep15179_CR20) 2009; 6
SF Adams (BFsrep15179_CR40) 2009; 115
ES Jordanova (BFsrep15179_CR45) 2008; 14
M Gerena-Lewis (BFsrep15179_CR43) 2009; 32
LS Peng (BFsrep15179_CR9) 2012; 61
M Yan (BFsrep15179_CR29) 2011; 13
S Sakaguchi (BFsrep15179_CR11) 2008; 133
A Ladanyi (BFsrep15179_CR27) 2010; 16
FA Sinicrope (BFsrep15179_CR46) 2009; 137
RJ deLeeuw (BFsrep15179_CR5) 2012; 18
SE Erdman (BFsrep15179_CR38) 2005; 65
Z Shen (BFsrep15179_CR4) 2010; 136
C Miracco (BFsrep15179_CR28) 2007; 18
J Carreras (BFsrep15179_CR35) 2006; 108
TJ Curiel (BFsrep15179_CR13) 2004; 10
P Salama (BFsrep15179_CR19) 2009; 27
N Leffers (BFsrep15179_CR2) 2009; 58
AL Gerber (BFsrep15179_CR25) 2014; 170
RP Petersen (BFsrep15179_CR15) 2006; 107
Q Gao (BFsrep15179_CR14) 2007; 25
SA Siddiqui (BFsrep15179_CR23) 2007; 13
AJ Schottelius (BFsrep15179_CR37) 2006; 130
G Perrone (BFsrep15179_CR16) 2008; 44
WS Lee (BFsrep15179_CR33) 2010; 116
GJ Bates (BFsrep15179_CR12) 2006; 24
F Venet (BFsrep15179_CR39) 2006; 177
References_xml – volume: 21
  start-page: 1539
  year: 2002
  end-page: 1558
  ident: CR22
  article-title: Quantifying heterogeneity in a meta-analysis
  publication-title: Stat Med
  doi: 10.1002/sim.1186
– volume: 44
  start-page: 1875
  year: 2008
  end-page: 1882
  ident: CR16
  article-title: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.05.017
– volume: 115
  start-page: 2891
  year: 2009
  end-page: 2902
  ident: CR40
  article-title: Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer
  publication-title: Cancer
  doi: 10.1002/cncr.24317
– volume: 10
  start-page: 942
  year: 2004
  end-page: 949
  ident: CR13
  article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
  publication-title: Nat Med
  doi: 10.1038/nm1093
– volume: 8
  start-page: 16
  year: 2007
  ident: CR21
  article-title: Practical methods for incorporating summary time-to-event data into meta-analysis
  publication-title: Trials
  doi: 10.1186/1745-6215-8-16
– volume: 108
  start-page: 2957
  year: 2006
  end-page: 2964
  ident: CR35
  article-title: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2006-04-018218
– volume: 65
  start-page: 3998
  year: 2005
  end-page: 4004
  ident: CR38
  article-title: CD4 CD25 regulatory lymphocytes induce regression of intestinal tumors in ApcMin/ mice
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-3104
– volume: 8
  start-page: 59
  year: 2011
  end-page: 66
  ident: CR17
  article-title: A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4( )FOXP3( ) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2010.56
– volume: 16
  start-page: 303
  year: 2010
  end-page: 309
  ident: CR27
  article-title: FOXP3 cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-010-9254-x
– volume: 91
  start-page: 1711
  year: 2004
  end-page: 1717
  ident: CR7
  article-title: Intraepithelial CD8 T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6602201
– volume: 136
  start-page: 1585
  year: 2010
  end-page: 1595
  ident: CR4
  article-title: Higher intratumoral infiltrated Foxp3 Treg numbers and Foxp3 /CD8 ratio are associated with adverse prognosis in resectable gastric cancer
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-010-0816-9
– volume: 27
  start-page: 186
  year: 2009
  end-page: 192
  ident: CR19
  article-title: Tumor-infiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.7229
– volume: 34
  start-page: 336
  year: 2004
  end-page: 344
  ident: CR42
  article-title: CD4 CD25 regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200324181
– volume: 30
  start-page: 1047
  year: 2013
  end-page: 1062
  ident: CR30
  article-title: Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3 Tregs
  publication-title: Clin Exp Metastasis
  doi: 10.1007/s10585-013-9602-9
– volume: 32
  start-page: 269
  year: 2009
  end-page: 273
  ident: CR43
  article-title: A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0b013e318187dd40
– volume: 130
  start-page: 67
  year: 2006
  end-page: 87
  ident: CR37
  article-title: Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer
  publication-title: Cancer Treat Res
  doi: 10.1007/0-387-26283-0_3
– volume: 13
  start-page: R47
  year: 2011
  ident: CR29
  article-title: Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression and is associated with poor prognosis in basal-like breast cancers
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2869
– volume: 107
  start-page: 2866
  year: 2006
  end-page: 2872
  ident: CR15
  article-title: Tumor infiltrating Foxp3 regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients
  publication-title: Cancer
  doi: 10.1002/cncr.22282
– volume: 18
  start-page: 3022
  year: 2012
  end-page: 3029
  ident: CR5
  article-title: The prognostic value of FoxP3 tumor-infiltrating lymphocytes in cancer: a critical review of the literature
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-3216
– volume: 6
  start-page: e1000097
  year: 2009
  ident: CR20
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000097
– volume: 299
  start-page: 1057
  year: 2003
  end-page: 1061
  ident: CR10
  article-title: Control of regulatory T cell development by the transcription factor Foxp3
  publication-title: Science
  doi: 10.1126/science.1079490
– volume: 13
  start-page: 2075
  year: 2007
  end-page: 2081
  ident: CR23
  article-title: Tumor-infiltrating Foxp3-CD4 CD25 T cells predict poor survival in renal cell carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2139
– volume: 108
  start-page: 155
  year: 2013
  end-page: 162
  ident: CR31
  article-title: Tumour-infiltrating FOXP3( ) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.524
– volume: 313
  start-page: 1960
  year: 2006
  end-page: 1964
  ident: CR1
  article-title: Type, density and location of immune cells within human colorectal tumors predict clinical outcome
  publication-title: Science.
  doi: 10.1126/science.1129139
– volume: 11
  start-page: 1467
  year: 2005
  end-page: 1473
  ident: CR34
  article-title: Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1869
– volume: 24
  start-page: 5373
  year: 2006
  end-page: 5380
  ident: CR12
  article-title: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.05.9584
– volume: 18
  start-page: 1115
  year: 2007
  end-page: 1122
  ident: CR28
  article-title: Utility of tumour-infiltrating CD25 FOXP3 regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma
  publication-title: Oncol Rep
– volume: 61
  start-page: 2183
  year: 2012
  end-page: 2192
  ident: CR9
  article-title: Increased tumor-infiltrating CD8( )Foxp3( ) T lymphocytes are associated with tumor progression in human gastric cancer
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-012-1277-6
– volume: 116
  start-page: 2224
  year: 2010
  end-page: 2233
  ident: CR26
  article-title: Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma
  publication-title: Cancer
– volume: 177
  start-page: 6540
  year: 2006
  end-page: 6547
  ident: CR39
  article-title: Human CD4 CD25 regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism
  publication-title: J Immunol
  doi: 10.4049/jimmunol.177.9.6540
– volume: 133
  start-page: 775
  year: 2008
  end-page: 787
  ident: CR11
  article-title: Regulatory T cells and immune tolerance
  publication-title: Cell
  doi: 10.1016/j.cell.2008.05.009
– volume: 116
  start-page: 5188
  year: 2010
  end-page: 5199
  ident: CR33
  article-title: Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer
  publication-title: Cancer
  doi: 10.1002/cncr.25293
– volume: 102
  start-page: 18538
  year: 2005
  end-page: 18543
  ident: CR3
  article-title: Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8 /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0509182102
– volume: 68
  start-page: 3907
  year: 2008
  end-page: 3914
  ident: CR36
  article-title: The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-6842
– volume: 70
  start-page: 7788
  year: 2010
  end-page: 99
  ident: CR44
  article-title: Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1736
– volume: 103
  start-page: 399
  year: 2009
  end-page: 405
  ident: CR24
  article-title: The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2008.08151.x
– volume: 58
  start-page: 449
  year: 2009
  end-page: 459
  ident: CR2
  article-title: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic le.sions of advanced stage ovarian cancer
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-008-0583-5
– volume: 7
  start-page: e42274
  year: 2012
  ident: CR8
  article-title: Prognostic impact of FoxP3 regulatory T cells in relation to CD8 T lymphocyte density in human colon carcinomas
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0042274
– volume: 170
  start-page: 103
  year: 2014
  end-page: 109
  ident: CR25
  article-title: High expression of FOXP3 in primary melanoma is associated with tumour progression
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.12641
– volume: 14
  start-page: 2028
  year: 2008
  end-page: 2035
  ident: CR45
  article-title: Human leukocyte antigen class I, MHC class I chain-related molecule A and CD8 /regulatory T-cell ratio: which variable determines survival of cervical cancer patients?
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4554
– volume: 126
  start-page: 2635
  year: 2010
  end-page: 2643
  ident: CR32
  article-title: High frequency of tumor-infiltrating FOXP3( ) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients
  publication-title: Int J Cancer
– volume: 25
  start-page: 2586
  year: 2007
  end-page: 2593
  ident: CR14
  article-title: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.4565
– volume: 113
  start-page: 1387
  year: 2008
  end-page: 1395
  ident: CR6
  article-title: Predominant infiltration of macrophages and CD8( ) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer
  publication-title: Cancer
  doi: 10.1002/cncr.23712
– volume: 4
  start-page: e6412
  year: 2009
  ident: CR41
  article-title: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0006412
– volume: 12
  start-page: 465
  year: 2006
  end-page: 472
  ident: CR18
  article-title: Prognostic value of tumor-infiltrating CD4 T-cell subpopulations in head and neck cancers
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-1886
– volume: 137
  start-page: 1270
  year: 2009
  end-page: 1279
  ident: CR46
  article-title: Intraepithelial effector (CD3 )/regulatory (FoxP3 ) T-cell ratio predicts a clinical outcome of human colon carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.06.053
– volume: 44
  start-page: 1875
  year: 2008
  ident: BFsrep15179_CR16
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.05.017
– volume: 11
  start-page: 1467
  year: 2005
  ident: BFsrep15179_CR34
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1869
– volume: 16
  start-page: 303
  year: 2010
  ident: BFsrep15179_CR27
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-010-9254-x
– volume: 12
  start-page: 465
  year: 2006
  ident: BFsrep15179_CR18
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-1886
– volume: 177
  start-page: 6540
  year: 2006
  ident: BFsrep15179_CR39
  publication-title: J Immunol
  doi: 10.4049/jimmunol.177.9.6540
– volume: 170
  start-page: 103
  year: 2014
  ident: BFsrep15179_CR25
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.12641
– volume: 113
  start-page: 1387
  year: 2008
  ident: BFsrep15179_CR6
  publication-title: Cancer
  doi: 10.1002/cncr.23712
– volume: 4
  start-page: e6412
  year: 2009
  ident: BFsrep15179_CR41
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0006412
– volume: 21
  start-page: 1539
  year: 2002
  ident: BFsrep15179_CR22
  publication-title: Stat Med
  doi: 10.1002/sim.1186
– volume: 58
  start-page: 449
  year: 2009
  ident: BFsrep15179_CR2
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-008-0583-5
– volume: 116
  start-page: 5188
  year: 2010
  ident: BFsrep15179_CR33
  publication-title: Cancer
  doi: 10.1002/cncr.25293
– volume: 70
  start-page: 7788
  year: 2010
  ident: BFsrep15179_CR44
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1736
– volume: 34
  start-page: 336
  year: 2004
  ident: BFsrep15179_CR42
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200324181
– volume: 8
  start-page: 16
  year: 2007
  ident: BFsrep15179_CR21
  publication-title: Trials
  doi: 10.1186/1745-6215-8-16
– volume: 65
  start-page: 3998
  year: 2005
  ident: BFsrep15179_CR38
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-3104
– volume: 13
  start-page: R47
  year: 2011
  ident: BFsrep15179_CR29
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2869
– volume: 91
  start-page: 1711
  year: 2004
  ident: BFsrep15179_CR7
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6602201
– volume: 25
  start-page: 2586
  year: 2007
  ident: BFsrep15179_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.4565
– volume: 102
  start-page: 18538
  year: 2005
  ident: BFsrep15179_CR3
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0509182102
– volume: 32
  start-page: 269
  year: 2009
  ident: BFsrep15179_CR43
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0b013e318187dd40
– volume: 126
  start-page: 2635
  year: 2010
  ident: BFsrep15179_CR32
  publication-title: Int J Cancer
  doi: 10.1002/ijc.24989
– volume: 299
  start-page: 1057
  year: 2003
  ident: BFsrep15179_CR10
  publication-title: Science
  doi: 10.1126/science.1079490
– volume: 8
  start-page: 59
  year: 2011
  ident: BFsrep15179_CR17
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2010.56
– volume: 30
  start-page: 1047
  year: 2013
  ident: BFsrep15179_CR30
  publication-title: Clin Exp Metastasis
  doi: 10.1007/s10585-013-9602-9
– volume: 115
  start-page: 2891
  year: 2009
  ident: BFsrep15179_CR40
  publication-title: Cancer
  doi: 10.1002/cncr.24317
– volume: 6
  start-page: e1000097
  year: 2009
  ident: BFsrep15179_CR20
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000097
– volume: 133
  start-page: 775
  year: 2008
  ident: BFsrep15179_CR11
  publication-title: Cell
  doi: 10.1016/j.cell.2008.05.009
– volume: 18
  start-page: 1115
  year: 2007
  ident: BFsrep15179_CR28
  publication-title: Oncol Rep
– volume: 116
  start-page: 2224
  year: 2010
  ident: BFsrep15179_CR26
  publication-title: Cancer
  doi: 10.1002/cncr.24999
– volume: 27
  start-page: 186
  year: 2009
  ident: BFsrep15179_CR19
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.7229
– volume: 7
  start-page: e42274
  year: 2012
  ident: BFsrep15179_CR8
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0042274
– volume: 136
  start-page: 1585
  year: 2010
  ident: BFsrep15179_CR4
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-010-0816-9
– volume: 107
  start-page: 2866
  year: 2006
  ident: BFsrep15179_CR15
  publication-title: Cancer
  doi: 10.1002/cncr.22282
– volume: 130
  start-page: 67
  year: 2006
  ident: BFsrep15179_CR37
  publication-title: Cancer Treat Res
  doi: 10.1007/0-387-26283-0_3
– volume: 61
  start-page: 2183
  year: 2012
  ident: BFsrep15179_CR9
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-012-1277-6
– volume: 10
  start-page: 942
  year: 2004
  ident: BFsrep15179_CR13
  publication-title: Nat Med
  doi: 10.1038/nm1093
– volume: 103
  start-page: 399
  year: 2009
  ident: BFsrep15179_CR24
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2008.08151.x
– volume: 14
  start-page: 2028
  year: 2008
  ident: BFsrep15179_CR45
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4554
– volume: 13
  start-page: 2075
  year: 2007
  ident: BFsrep15179_CR23
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2139
– volume: 68
  start-page: 3907
  year: 2008
  ident: BFsrep15179_CR36
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-6842
– volume: 108
  start-page: 2957
  year: 2006
  ident: BFsrep15179_CR35
  publication-title: Blood
  doi: 10.1182/blood-2006-04-018218
– volume: 313
  start-page: 1960
  year: 2006
  ident: BFsrep15179_CR1
  publication-title: Science.
  doi: 10.1126/science.1129139
– volume: 24
  start-page: 5373
  year: 2006
  ident: BFsrep15179_CR12
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.05.9584
– volume: 137
  start-page: 1270
  year: 2009
  ident: BFsrep15179_CR46
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.06.053
– volume: 108
  start-page: 155
  year: 2013
  ident: BFsrep15179_CR31
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.524
– volume: 18
  start-page: 3022
  year: 2012
  ident: BFsrep15179_CR5
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-3216
SSID ssj0000529419
Score 2.6370158
SecondaryResourceType review_article
Snippet The prognostic value of FoxP3 + regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3 +...
The prognostic value of FoxP3(+) regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3(+)...
The prognostic value of FoxP3+ regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3+...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 15179
SubjectTerms 692/499
692/53
Biomarkers, Tumor - metabolism
Breast cancer
Cancer
Esophageal cancer
Esophagus
Female
Forkhead Transcription Factors - immunology
Foxp3 protein
Head and neck
Humanities and Social Sciences
Humans
Immunoregulation
Kidneys
Lymphocytes T
Male
Meta-analysis
Metastases
multidisciplinary
Neoplasms - immunology
Neoplasms - mortality
Neoplasms - pathology
Prevalence
Prognosis
Reproducibility of Results
Risk Assessment - methods
Science
Sensitivity and Specificity
Solid tumors
Survival
Survival Rate
T-Lymphocytes, Regulatory - immunology
T-Lymphocytes, Regulatory - pathology
Tumors
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fT9wwDLbYoUl7QRtsowOmwPYwaYrojzRt9oI2BEKThk4TSLxVSZpsJ0F76_Ue-O9x2rTsAPEcS7Vix_5ip58BPvNQKMcqTuPSKspMaKlAWEBFHGthRGZZZ-lf5_zskv28Sq98wW3hn1UOMbEL1GWtXY38MMKLAV7XWM6P5v-omxrluqt-hMYLWMcQnKcTWP9xcj79PVZZXB-LRWKgFEryQ0w888jxUq0mokfo8vEjyQed0i4Bnb6GDY8cyffe1G9gzVSb8LKfJXm7Bc20qd2jOVwljsHbkNqSdnlTNxSdaHbd0eNWfwimm2nylTT9DPq6uSUXxFXvF2RWEe18oFl8I5LcUzyT_vcWIquS3JhWUumJTN7C5enJxfEZ9QMVqGZJ3lJhjSqtlankXHDLZB5ZEUodhQJjjWRoLs1MwlOFOExlWiTSOP4zgTiJK4SC72BS1ZXZBiJjqcs0R_yD97nQaKES3OlYmVTImIsogC_D7hbas427oRfXRdf1TvJiNEQAB6PovKfYeEpodzBR4U_Zorj3iQD2x2U8H27bZGXqJcpkCFJctzUP4H1v0fErCAa5Y6QPIFux9SjguLdXV6rZ346Dm_GQsSwO4NPgFf-p9VD5D88rvwOvEIZ1hLAR24VJ2yzNHkKdVn30_nwHSMIC0w
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals (WRLC)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ1JS8UwEMcHFwQv4m7diMtBkGCXNG28yUMRQfGg4K0keYk-0Fb6-g5-eyfd9KkHz5nSkEky_zTT3wAcc18oRxWn4dAqyoxvqUBZQEUYamFEYlnt6ds7fv3Ibp7ipxYWPW7TKhukZb1Nd9lhZxgv3gOHk5qFeUdsd5j8AR_0n1PchRULRMcOitKvJ6Yjzi8Z-Tsb8seVaB1prpZhqZWI5KLp1ArMmHwVFpqikR9rUN6XhcuOw1biUN2GFJZUk7eipDhbRq81Bzd_JhhX7qNTUjbF5ovygzwQ95l-TEY50c7Z5ficSPLFcibNfyxE5kPyZipJZUssWYfHq8uHwTVtKydQzaK0osIaNbRWxpJzwS2TaWCFL3XgC9xUJEO_aGYiHisUXCrRIpLGgc4ECiKuUPNtwFxe5GYLiAylHsYpCh08uPlGCxXhSIfKxEKGXAQenHSjm-kWK-6qW7xm9fV2lGa9Izw47E3fG5bGX0a7nYuydjmNswBPhXhWZyn34KBvxoXghk3mppigTYJqxF2rph5sNh7t34Kqjzv0vAfJlK97AwfZnm7JRy81bJtxn7Ek9OComxXfuvWz89v_stqBRZRdNQA2YLswV5UTs4fSplL79aT-BNNm_DQ
  priority: 102
  providerName: Springer Nature
Title Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
URI https://link.springer.com/article/10.1038/srep15179
https://www.ncbi.nlm.nih.gov/pubmed/26462617
https://www.proquest.com/docview/1899788486
https://www.proquest.com/docview/1722420368
https://pubmed.ncbi.nlm.nih.gov/PMC4604472
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9swED_6YLAvY--564L2-DAYWv2QZWswRhZaSqAlbA3km5EUaQukdus4sPz3O_m1pu2nfTJYZ1u-O_l-J8m_A_jAfaEcqzgN51ZRZnxLBcICKsJQCyMSy2pLn53z0ykbz-LZDnQ1NlsFru5N7Vw9qWm5_PznevMNB_zX5pfx9AhjyVXgqKZ2YR8DEnfOfdai_IbiOxQsEB2v0M0rHBcwZ9zRkm8Hpjto8-6myVsrp3VAOnkMj1okSYaN6Z_AjsmfwoOmtuTmGZSTsnCb6LCVOEZvQwpLqvVlUVJ8zcWypsvNfxEMP5PoEymbmvRFuSEXxM3mr8giJ9r5RLn6QiT5R_lMmt9diMzn5NJUksqW2OQ5TE-OL0antC2wQDWL0ooKa9TcWhlLzgW3TKaBFb7UgS_w2yMZmk8zE_FYIS5TiRaRNI4PTSBu4gqh4QvYy4vcvAIiQ6nncYp6xPzON1qoCJUeKhMLGXIRePCx026mW_ZxVwRjmdWr4FGa9Tbx4F0vetVQbtwndNiZKOucJgswecSUnqXcg7d9M44XpzaZm2KNMgmCFrf6mnrwsrFo_5TOFTxItmzdCzgu7u2WfPG75uRm3GcsCT1433nFjW7d7vzBf9__NTxExFZzxwbsEPaqcm3eICqq1AB2k1kygP3hcPxzjMfvx-eTH3h2xEeDeqZhUI-Kv23pFog
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Za9wwEB5CQmlfStLTbdqqFxSKiA9Ztgql9EjYNMmylA3kzZFkOVlI7I3XS9k_ld_Yka90k9K3PGvAwxyaTx7pG4B33BXKsopTP80UZcbNqEBYQIXva2FElLHa0wdDPjhkP4_CoxW47N7C2GuV3Z5Yb9Rpoe0_8i0PDwZ4XGMx_zK9oHZqlO2udiM0mrDYM4vfeGSbfd79gf597_s72-PvA9pOFaCaBXFFRWZUmmUylJwLnjEZe5lwpfZcgQknGeqsmQl4qBCMqEiLQBpLAiYQLHAlLNEBbvlrCDMEZtHat-3h6Ff_V8f2zZgnOgqjIN7CQjf1LA_WcuG7gWZvXsq81pmtC97OOtxvkSr52oTWBqyY_AHcaWZXLh5COSoLe0kPV4llDDekyEg1Py9KikE7OavpePMTguVtFHwkZTPzvigXZExst2BGJjnRNubK2SciyRWlNGme0xCZp-TcVJLKljjlERzeiqkfw2pe5OYpEOlLnYYx4i08P7pGCxWgpX1lQiF9LjwHPnTWTXTLbm6HbJwldZc9iJPeEQ686UWnDaXHv4Q2OxclbVbPkqsYdOB1v4z5aM0mc1PMUSZCUGS7u7EDTxqP9l9B8MktA74D0ZKvewHL9b28kk9Oa85vxl3GIt-Bt11U_KXWdeWf_V_5V3B3MD7YT_Z3h3vP4R5CwJqM1mObsFqVc_MCYValXraxTeD4ttPpD7KTQDI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1taxQxEB7KFcUvxfeuVo1vIEi4fclmN4Uianu0Vo9DWui3bTab1IN299zbQ-6v-euc7Fu9VvzWzwlsNjOTeSYzeQbgDXdFalnFqZ-ZlDLtGioQFlDh-0poERlWS_rbmO8fsy8n4cka_O7ewtiyyu5MrA_qrFD2jnzoYWCA4RqL-dC0ZRGT3dGH2U9qO0jZTGvXTqNRkUO9_IXh23znYBdl_db3R3tHn_dp22GAKhbEFRVGp5kxMpScC26YjD0jXKk8V6DxSYbrV0wHPEwRmKSREoHUlhBMIHDgqbCkB3j8r0f4Q_EA1j_tjSff-xsem0NjnujojIJ4iE5v5llOrFUneA3ZXi_QvJKlrZ3f6C5stKiVfGzU7B6s6fw-3Gr6WC4fQDkpC1uwh6PEsodrUhhSLS6KkqICT89rat78jKCrmwTvSanPbNOwolySI2IzB3MyzYmy-lfOt4kkl_TSpHlaQ2SekQtdSSpbEpWHcHwjW_0IBnmR600g0pcqC2PEXhhLulqJNMCd9lMdCulz4TnwrtvdRLVM57bhxnlSZ9yDOOkF4cCrfuqsoff416StTkRJa-Hz5FIfHXjZD6Nt2m2TuS4WOCdCgGQzvbEDjxuJ9l9BIMotG74D0Yqs-wmW93t1JJ_-qPm_GXcZi3wHXnda8deyri7-yf8X_wJuoxklXw_Gh0_hDqLBmpfWY1swqMqFfoaIq0qft6pN4PSmrekPG5pEXg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+tumor-infiltrating+FoxP3%2B+regulatory+T+cells+in+cancers%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Scientific+reports&rft.au=Shang%2C+Bin&rft.au=Liu%2C+Yao&rft.au=Jiang%2C+Shu-juan&rft.au=Liu%2C+Yi&rft.date=2015-10-14&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=5&rft_id=info:doi/10.1038%2Fsrep15179&rft_id=info%3Apmid%2F26462617&rft.externalDocID=PMC4604472
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon